Recombinant Human LR3 IGF-I Protein
-
产品编号
KRP683
-
别名
重组人LR3 IGF1蛋白，Long R3 IGF-I, LR3 Insulin-like growth factor I, Insulin-like growth factor 1, IGF-I LR3, IGFI,
-
规格
- 100ug
- 500ug
- 1mg
产品介绍
| Catalog Number | KRP683 |
| Alias | 重组人LR3 IGF1蛋白，Long R3 IGF-I, LR3 Insulin-like growth factor I, Insulin-like growth factor 1, IGF-I LR3, IGFI, |
| Size | 100ug,500ug,1mg |
| Product Full Name | Recombinant Human LR3 IGF-I Protein |
| Molecular Name | IGF1 |
| Product Introduction | 重组人长效IGF-1变体（LR3 IGF-1），具有增强的稳定性与生物活性。适用于长效细胞增殖研究、肌肉再生实验及代谢疾病相关机制探索。 |
| Molecular Weight | 8 kDa |
| Target | LR3 IGF-I |
| Expression System | E.coli |
| Species | Human |
| Concentration | 联系销售经理获得最新批次的浓度 |
| Purity | >97%, determined by SDS-PAGE. |
| Purification | Affinity Purification |
| Uniprot ID | P05019 |
| Storage Condition | Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Avoid repeated freeze-thaw cycles. |
| Temperature Range | Store the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -27℃. Avoid repeated freeze-thaw cycles. |
| Shipping Condition | This product is shipped on ice packs or dry ice. |
| Background | IGF-1的一种长效类似物，通过氨基酸替换和N端延伸肽（R3）降低其与结合蛋白（IGFBP）的亲和力，从而增强其生物活性和稳定性，主要用于科学研究。 |
| Endotoxin | <0.01 EU/μg, determined by LAL method. |
| Predicted Molecular Weight | 9 kDa |
| Application | WB, ELISA |
| Reconstitution | It is recommended that the lyophilized human LR3 IGF-I protein be dissolved in 100 mM Acetic Acid at a concentration of 100-200 μg/mL for further dilution as the working concentration. |
| Stability | Repeated freezing and thawing is not recommended. |
| References | 1. Philippou, A. et al. (2007) In Vivo 21:45. 2. Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275. 3. Berryman, D.E. et al. (2013) Nat. Rev. Endocrinol. 9:346. 4. Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890. 5. Sadagurski, M. and M.F. White (2013) Endocrinol. Metab. Clin. North Am. 42:127. 6. Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620. 7. Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577. 8. Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275. 9. Malemud, C.J. (2007) Clin. Chim. Acta 375:10. 10. Ling, P.R. et al. (1995) Am. J. Clin. Nutr. 61:116. 11. Sheng, M.H. et al. (2014) J. Bone Metab. 21:41. 12. Samani, A.A. et al. (2007) Endocrine Rev. 28:20. 13. Gallagher, E.J. et al. (2010) Endocr. Pract. 16:864. 14. LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302. 15. Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421. 16. Duan, C. and Q. Xu (2005) Gen. Comp. Endocrinol. 142:44. 17. Francis, G.L. et al. (1992) J. Mol. Endocrinol. 8:213. 18. Voorhamme, D. and C.A. Yandell (2006) Mol. Biotechnol. 34:201. 19. Tomas, F.M. et al. (1993) Biochem. J. 291:781. 20. Tomas, F.M. et al. (1996) J. Endocrinol. 150:77. 21. Tomas, F.M. et al. (1997) J. Endocrinol. 155:377. 22. von der Thüsen, J.H. et al. (2011) Am. J. Pathol. 178:924 |
| Function | 重组人长效IGF-1变体（LR3 IGF-1），具有增强的稳定性与生物活性。适用于长效细胞增殖研究、肌肉再生实验及代谢疾病相关机制探索。 |
| Product Declaration | 该产品仅供科研使用，不可直接用于人体或注射。 |
FAQ
-
LR3 IGF-1和普通IGF-1有什么区别？它是IGF-1的类似物，与IGF-1受体结合亲和力更强，且在体内的半衰期显著延长。
在培养中何时选择使用它？当需要更强劲、更持久的促生长和抗凋亡信号时使用，例如在高密度干细胞扩增或细胞处于应激条件时。
- 联系我们
- 电话：400-621-6806
- 手机：13116038708
- 邮箱：info@kmdbioscience.com
- 地址：天津市武清区国际企业社区A5栋
-
销售微信
-
官方公众号
-
400-621-6806 -
13116038708（微信同号） -
周一至周五 8:30-18:00 -
-
0
-
